Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

NCT01332721 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Adult Solid Tumor

Interventions

DRUG: TRC105 and Bevacizumab

Sponsor

Tracon Pharmaceuticals Inc.